Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from AC Immune SA ( (ACIU) ).
On February 24, 2026, AC Immune SA reported that it has dosed the first participant in a Phase 1 clinical trial of ACI-19764, an orally administered, highly brain-penetrant small molecule inhibitor of the NLRP3 inflammasome. The candidate is positioned as an important extension of the company’s small-molecule pipeline, aimed at addressing chronic inflammation implicated in metabolic disorders and neurodegenerative conditions such as Alzheimer’s, Parkinson’s, ALS and frontotemporal dementia.
The Phase 1 study in healthy volunteers in Europe will assess safety, tolerability, pharmacokinetics and pharmacodynamics through single and multiple ascending doses, with initial data expected in the second half of 2026. Preclinical results showed strong potency, brain penetration, and promising effects on neuroinflammation and weight control, potentially placing ACI-19764 among the more competitive NLRP3 inhibitors for central nervous system and metabolic indications and underscoring AC Immune’s push to broaden its clinical portfolio.
The most recent analyst rating on (ACIU) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
The score is held down primarily by weak financial performance (sharp TTM revenue decline, persistent losses, and renewed cash burn) and a loss-making valuation profile (negative P/E, no dividend yield). These are partially offset by a solid balance-sheet leverage position and supportive technicals with price above key moving averages and positive MACD.
To see Spark’s full report on ACIU stock, click here.
More about AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision prevention and treatment of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and rare NeuroOrphan indications linked to misfolded proteins. It leverages its SupraAntigen and Morphomer technology platforms to develop first- and best-in-class therapeutic and diagnostic candidates, supported by partnerships with major pharmaceutical groups that provide significant non-dilutive funding and milestone potential.
Average Trading Volume: 716,416
Technical Sentiment Signal: Strong Sell
Current Market Cap: $259.2M
For an in-depth examination of ACIU stock, go to TipRanks’ Overview page.